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Malignant disease is seen as an active contest between host and tumour rather than an autonomous growth ofa tumour in an indifferent environment (Prehn & Main 1957 , Klein et al. 1960 , Old et al. 1961 . That the host response is partly immunological is supported by clinical observations (Table I ). The concept of tumour immunology stems from the main root of immunology, namely the study of infectious diseases. and from the growing understanding of homograft reactions in transplantation surgery. Although immune surveillance in cancer (Ehrlich 1909 , Thomas 1959 , Burnet 1971 can be questioned (Stutman 1975) , it has been a permanent hypothesis that the host's immune system is capable of recognizing new molecular properties (antigens) displayed by the tumour cell as a result of the physicobiochemical changes that take place during the transition from normal to malignant. The existence of such new antigens in a tumour was probably first indicated in 1929 by Witebsky using rabbit sera raised against human tumour extracts. in a complement fixation test. A first confirmation of a specific immune response to new tumour antigens (Gross 1943 . Foley 1953 . Prehn & Main 1957 became possible with the development of genetically identical mice; these rejected a second transplant of a chemically induced tumour but tolerated a repeated challenge with normal cells from the mouse from which the tumour transplant had been taken. Since then a wide range of methods (Table 2) has been tried to dissect and manipulate the anti tumour immune response in animal and to a limited extent -in human (Baldwin 1974 , Herberman 1977 , Moore 1978 . Cellular and humoral immunity may be involved. Serological techniques. using auto-and hetero-sera (Table 2 (C» against tumours and their normal counterparts, allow the identification and classification of tumour antigens and link immunological to morphological and biochemical tumour analysis. It has been established not only that a tumour can acquire antigens not present in the tissue of origin, but also that it can increase or lose antigens already present in the normal cell. Table 3 . based on the distinction between organ and new tumour antigens. lists these three possibilities and. as a fourth possibility, combinations of them. Certainly. the use of more sensitive tests and their wider application will alter this preliminary grouping of tumour associated antigens (T AA). Complement-dependent haemolysis in indicator system (SRBChaemolytic antiserum) prevented by complement-fixing tu antigenantibody complex Maximum precipitation in mixture of homogenous tu antigen and antiserum at optimal proportions Diffusion of antigen and antibody in gels and precipitation of antigen-antibody aggregates at optimal proportions Displacement of radioactively labelled tu antigen from fixed antibody by identical but unlabelled antigen under quantitation Occupation of tu bearer's Iy cells by circulating shed tu antigen in serum from host with progressive tu Occupation of tu bearer's Iy cells by circulating tu antigenantibody complexes in serum from host with progressive tu Free tu antigen sites in blocking serum saturated by tu antibody excess in serum from host with regressive tu Complement-independent destruction of tu cells by anti tu IgO bound to Fe receptors of nonspecific ly (T,K,null) cells
Fe, crystallizable fragment of antibody Ig, immunoglobulin K, killer cells SRBC, sheep red blood cells T, thymus-dependent lymphocytes ly, lymphoid tu, tumour (2) those shared between a number of tumours;
(3) antigens shared between a given tumour and normal cells, other than the cell of tumour origin, in the host. A given tumour may express all three classes of antigen. The first two classes include antigens demonstrable by transplantation experiments in animals, termed tumour-specific transplantation antigens (TSTA), and antigens demonstrated serologically in human tumours. The classical example for tumour-unique antigens is the TSTA ofchemically induced tumours. Virally induced tumours, on the other hand, share common antigens, even when induced in animals of different species (Hellstrom & Sjogren 1967) . In man, tumour-unique antigens have been claimed to exist in melanomas (Shiku et al. 1976 ),tumour-common antigens in sarcomas (Morton et al. 1969 )and also in melanomas (Carrel & Theilkaes 1973 ,Viza & Phillips 1975 ,Shiku et al. 1976 ).Oncofetal antigens, too, appear to belong to the class of tumour-common antigens. Alphafetoprotein (AFP), found in the embryo and in sera of pregnant women, is shared by hepatomas and germ cell tumours ofthe adult (Abelev 1968) . It is, however, also detectable in nonmalignant diseases (Waldmann & McIntire 1972 , Silver et al. 1974 ). Both tumour-unique and tumour-common antigens are theoretically new to the tumour bearer. They may be termed tumour-specific antigens (TSA). In contradistinction, the third group of new antigens is new only to the cell of tumour origin, but is present in other tissues of the tumour host. Blood group antigens, for example, not present in normal mucosa of the distal colon, appear in the corresponding carcinomas (Denk et al. 1974) . Ectopic secretion of hormones in tumours of nonendocrine origin was noted early (Brown 1928 , Meador et al. 1962 .
The physicochemical nature of the new tumour antigens of classes (1) and (2) is not well defined. The existence of truly new tumour antigens in the sense of absolutely new biological entities is, however, most unlikely. Unique tumour antigens in chemically induced mouse tumours have been shown to beidentical with normal histocompatibility antigens of allogeneic strains (Invernizzi & Parmiani 1975 , Bowen & Baldwin 1975 . Virally induced tumours can express histocompatibility (Garrido et al. 1976 )and organ-specific antigens (Boyse et al. 1968) of other strains, as well as fetal antigens (Coggin & Anderson 1974) , besides virion-related antigens. The heterogenetic Paul-Bunnell antigen is a normal constituent of all cells in bovine and of certain cellsin murine species. It is absent from all normal human cells. But it appears on human malignant lymphoid cells (Milgrom et al. 1975) . Many new tumour antigens may be an expression of genes l silent in the normal cell. New antigens may reflect a change or a shift of pre-existing molecules. The definition of new tumour antigens depends on the sensitivity of the applied bioassay. More sensitive tests will narrow the number of qualitatively distinct tumour antigens and reveal that, in many cases, a tumour has increased amounts of antigens that are already constituents of the precursor cell. Carcinoembryonic antigens (CEA), for example, seemed to be specific for human colon carcinomas, when immunodiffusion techniques were used (Gold & Freedman 1965) . The wide application of the radioimmunoassay showed it to be present also in nonmalignant conditions of the adult bowel (MacSween et al. 1973) .Tumours with ectopic hormone production could arise from single, normally inconspicuous, hormone producing cells of the APUD (amine precursor uptake and decarboxylation) system within the enteropancreatic and respiratory organs (Pearse 1977).
Organ antigens (Table 3(B), (C»
Thus, many TAA may be antigens of the normal precursor cell. Normal TAA can be divided into: antigens shared with other tissues; and organ (tissue) specific antigens (OSA). The first group includes, for example, blood group, histocompatibility and heterogenetic antigens, which are widely distributed not only within different tissues of one individuum but also randomly shared by animals, plants and bacteria. Organ-specific antigens, on the other hand, are qualitatively distinct from similar substances in other organs and tissues of the body and can broadly be categorized as cell products and as cell structures (Dumonde 1966) . They appear early in embryogenesis as an expression of cell differentiation (Okada 1965 )and may be involved in cell organization and tissue homeostatic control (Green & Anthony 1963 , Bullough 1965 ). Since they are characteristic for morphological and functional units, their presence in different species may reflect evolutionary relationships (Nairn et al. 1962 ,Nairn et al. 1967 .As with TSA, not much is known about their biochemical structures. One of the best studied OSAs is thyroglobulin, the antigen involved in Hashimoto's thyroiditis and primary myxoedema (Doniach et al. 1960) .The modification of organ-specific antigens seems to play an important part in the development of autoimmune diseases (Weigle 1965) .
Autoimmune reactions may also be connected with carcinogenesis. In organ-specific autoimmune diseases, such as ulcerative colitis or pernicious anaemia, the incidence of carcinomas of colon and stomach is much higher than in the general population. In malignancies, retention, gain (Pikovski & Witz 1961 , Walford et al. 1971 )and deletion (Weiler 1956 ,Jeannet & Magnin 1971 ,Kay & Wallace 1961 ,Gupta 1976 )ofnormal antigens have been described. Deletion of organ-specific antigens could be associated with a loss of tissuehomeostatic control mechanisms (Burch 1963) . Gain and loss of normal antigens in a tumour cell may be linked. Furthermore, loss of normal antigens can occur together with the gain of new tumour antigens. For instance, an inverse quantitative relationship has been observed between Hz and TSTA in chemically induced murine sarcomas (Haywood & McKhann 1971) . this suggests the same mechanisms in their phenotypic expression. Theoretically, deletion of enzymes suppressing DNA replication could lead to derepression of silent genes and even to uncontrolled cell replication (Day 1965 ,Potter 1969 .The resulting cancer cell would express a new antigenic profile.
Work on bladder and lung epithelial antigens
Antigenic changes can occur on the cell surface and inside the cell. T AA, in order to be recognized as foreign by the immune system, must be exposed to the host and either be expressed on the cell surface or besecreted by the tumour cells. Antigens new to the tumour bearer and also all types of pre-existing normal antigens, as demonstrable mautoimmune diseases, may thus become immunogenic. In contrast, many antigenic changes may not be recognized by the immune system, mainly when they take place inside the cell. This may be the case with cell-organelle-associated organ-specific antigens but equally with new' tumour antigens. Identification and purification ofall types ofTAA should be of diagnostic value; that of immunologically provocative new antigens, particularly common TSA will, in addition, be of potential use for immunotherapy.
Our own work (in preparation) is based on the considerations that there may be organspecific antigens in normal and malignant cells and tumour-specific antigens in malignant cells; and that both types of antigen could be expected on the cell surface and inside the cell. We have started comparing immunologically (leaving nuclear aspects aside for the moment) cytoplasm and cell surface of normal and malignant lung and urinary bladder epithelium (Figure 1) . For the study of normal bladder epithelium, we have used calf bladders, since we need many viable urothelial cells from healthy donors. As malignant counterpart, we used the RT4 cell line, derived from a well differentiated papillary bladder tumour (Rigby & Franks 1970) . Results Table 4 . Tumour-associated antigens (TAA) (2) Serology: titre ofTAA and antibodies in serum and urine (a) normal urothelial antigens and antibodies (b) new tumour antigens and antibodies (3) Scanning: localization of antigens in primary and metastases with (radio-) labelled antibodies (a) tumour-specific antigens (TSA) -'hot' primary and metastases (b) organ-specific antigens (OSA) -deletion: 'cold' primary in 'hot' urothelium ; retention or gain: 'hot' primary, organ and metastases potential therapy Active immunization with purified immunogenic TSA: prophylactic; therapeutic. Passive immunizationimmunological excision of tumour nodules by local or sytemic application of cytotoxic, nonenhancing antibodies against TSA. Linking therapeutics to antibodies: cytotoxic material to antibodies against TSA; protective material to antibodies against normal urothelial antigens prior to cytotoxic treatment of tumour (3) (2) (I) (2) (1) (2) obtained by indirect immunofluorescence with rabbit antisera suggest that urothelium contains two main groups of antigens, distinguishable by steps of absorption with normal organs: (I) common epithelial antigens, shared by urothelium and collecting ducts of the kidney, bile ducts of the liver, excretory ducts of the pancreas and epithelia of other organs; (2) urothelium-specific antigens, concentrated in the luminal parts of the transitional cell layer. Both groups of antigens are not species specific. They have been detected in bladders from human, calf, rat, mouse; and also in human bladder carcinomas, including the RT4 cell line. A quantitative comparison of these antigens in normal and in different grades of malignant urothelium should indicate whether antigen content and tumour differentiation show any correlation. The main result ofour investigations of a mouse lung system (Franks et al. 1976 )is that the tumour (CMT64) has lost normal antigens. Antisera against normal mouse lung still show, after absorption with other normal mouse organs, immunofluorescence with bronchial epithelium and single alveolar cells, but fail to react with the tumour in the same lung.
Future approach
The identification with indirect immunofluorescence of bladder and lung epithelial antigens is only a first step in the complete characterization of the normal and of the malignant cell antigenic pattern. Tables 4 & 5 summarize possibilities in basic research, clinical studies and therapy. At this stage, our preparations of the organ antigens are complex mixtures of macromolecules. More sensitive techniques will restrict the spectrum and distinguish between qualitative and quantitative specificities. Work is in progress on determination of molecular size and electron-microscopical localization of these antigens. Clinically, organ-specific antigens will be useful for the differential diagnosis of metastases, for monitoring treatment and, hypothetically, for grading and staging of tumours, and for assessing prognosis. Some evidence for the existence of new tumour-common antigens on human transitional cell carcinomas (Bloom 1976 , Herr 1976 gives hope that, in addition, early tumour diagnosis and screening of whole populations will become feasible for the urologist. With the-antigenic side known, the study of host immune responses will become more precise and eventually allow successful immunotherapy.
